H&H International Investment LLC Has $2.35 Million Stock Position in Moderna, Inc. $MRNA

Key Points

• H&H International Investment LLC has reduced its stake in Moderna by 49.1%, selling 80,000 shares and leaving it with 83,000 shares valued at approximately $2.35 million.
• Moderna's stock currently has an average analyst rating of "Hold" with a consensus price target of $42.88, despite recent price reductions from major banks.
• The company reported a net loss of ($2.13) per share in its latest earnings report, which was better than analysts' expectations, but reflects a substantial 41.1% decline in revenue year-over-year.

H&H International Investment LLC decreased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 49.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,000 shares of the company's stock after selling 80,000 shares during the period. Moderna accounts for approximately 0.0% of H&H International Investment LLC's holdings, making the stock its 11th largest position. H&H International Investment LLC's holdings in Moderna were worth $2,353,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of MRNA. Theleme Partners LLP boosted its position in Moderna by 1.0% during the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after purchasing an additional 72,028 shares during the last quarter. Invesco Ltd. raised its stake in shares of Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after purchasing an additional 877,162 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock valued at $88,441,000 after buying an additional 160,572 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after buying an additional 285,662 shares in the last quarter. Finally, Voloridge Investment Management LLC grew its stake in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after buying an additional 1,996,003 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Trading Up 3.5%

Shares of NASDAQ:MRNA traded up $0.86 during trading on Friday, reaching $25.14. 13,009,398 shares of the stock were exchanged, compared to its average volume of 9,059,473. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $79.96. The stock has a 50-day moving average price of $28.84 and a 200-day moving average price of $28.50. The firm has a market cap of $9.78 billion, a PE ratio of -3.34 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm's quarterly revenue was down 41.1% compared to the same quarter last year. During the same quarter last year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRNA shares. Bank of America dropped their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research report on Tuesday, July 22nd. Leerink Partners lowered their price objective on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research note on Friday, August 22nd. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Barclays reduced their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Finally, Citigroup started coverage on Moderna in a research note on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $42.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.